allergies >> yeah, they have things in the pipeline from milk and eggs and other companies like regeneron which is trying to develop drugs from blocking allergic reactions from taking effect at all, like cat dander and pollen. >> thank you so much >>> dr. scott sicherer is from mt. sinai in new york and the author of "food allergies, a complete guide to eating when your life depends on it. thank you for being here today. >> thank you. >> meg pointed this out in her piece, but it seems like there are so many more allergies than 10 or 20 years ago why is that? >> look at the peanut allergy, it tripled from 1 in 250 children to 1 in 70. it's almost an epidemic. >> are we better at catching this or kids are so much more allergic >>, no, this is real people who look in classrooms now you're seeing 1 in 13 children, two per classroom with food allergies it's not just our imagination. we don't know exactly why. one theory is this cleanliness theory because our immune system is the part of the body that protects us from germs but for allergy to attack the food and it makes us sick and we have cle

regeneron. allergan. >> why would tesla be moving? liz: good thing he's not egocentric here. let's bring in our traders. alan is standing by, chris robinson is in the chair. chris, what are you noticing on a day we are now up highs of the session, 524 points of gains, about 18 minutes left of trade? >> well, it comes down to percentages. we broke 7% last week. we have come back almost 3.5%, halfway back trade. i want to see how we settle on the week. you have to get used to this type of volatility. i keep saying that. in 2018, it's shaping up to be a year where the dow will be in a 4,000 point trading range and we saw it in january. we rallied back 4,000 points. we just broke 2,000 points. now from the bottom to the top, we are back 800. you have to get used to these percentage moves. i don't know if we will make new highs or new lows, but you have to get used to this type of volatility. liz: yeah. i would agree with that. alan, okay, let's just say volatility is back. where are you seeing the smart money invest right now, or are they simply going to cash on a day like this w

adobe and advanced micro alexion and regeneron and on the insurer front from united health care, we're seeing gains, strong ones across the board. coming up, much more from the marks and thrive riyadh on the investigation into the alleged murder of journalist jamal khashoggi. what do advisors look for in an etf? i tell clients, etfs can follow an index, but which ones target your goals? it's not about quantity. it's about quality. no trendy stuff. i want etfs backed by research. is it built for the long-term? my reputation depends on it. flexshares etfs are designed and managed around investor objectives. so you can advise with confidence. before investing, consider the fund's investment objectives, risks, charges and expenses. go to flexshares.com for a prospectus containing this information. read it carefully. you mighyour joints...ng for your heart... or your digestion... so why wouldn't you take something for the most important part of you... your brain. with an ingredient originally discovered in jellyfish, prevagen has been shown in clinical trials to improve short-term memory. p

the biggest ones was regeneron's ilea these are the most recent numbers from the centers for medicaides they're proposing tieing payment of those drugs to an international average of what 17 countries similar to the united states in terms of their economics pay for these medicines. they want to do that because they -- trump has been saying for a long time other countries pay a lot less for their drugs than we do, and if you look at the top 20 medicare part "b" drugs in 2016, from the health and human services department today, $17.2 billion was the medicare part "b" spending compared with the average $9.1 billion from other countries they say on average this should save 30% on what we're paying on these drugs. they're proposing paying 126% of the average in terms of what they reimburse for these drugs pegging it to the international prices. >> would this necessarily mean the drug companies make less money? >> it could. >> not like the stocks are falling on this news i can tell you those prospects amgen is not falling, pardon me -- >> we know that they don't necessarily collect a list